Intralesional immunotherapy of malignant melanoma with mycobacterium smegmatis cell wall skeleton combined with trehalose dimycolate (p3)

The clinical efficacy of intralesional immunotherapy utilizing Mycobacterium smegmatis cell wall skeleton (CWS) and trehalose dimycolate attached to oil droplets was investigated in 15 patients with advanced malignant melanoma. Patients received 300 μg to 1050 μg of the CWS combined with one‐half that amount of trehalose dimycolate every 1 to 2 weeks for a total of 8 treatments. Therapy was continued if regression of injected lesions only occurred. Therapy was discontinued if regression of noninjected disease also occurred. Six of the 15 patients had regressionof at least one injected lesion. Four of these 6 patients also had regression of noninjected disease lasting 4+, 6, 16 and 18+ months. Response was highly related to immune status. Six (83%) of 7 patients who reacted to one of a battery of skin tests responded. All 8 patients who did not react to skin tests failed to respond to therapy. There was no correlation of response with sex, prior therapy, disease‐free interval or presence of visceral disease. Mycobacterial CWS and trehalose dimycolate is an effective immunotherapeutic agent. Additional studies of purified immunoadjuvants are warranted. Cancer 44:495‐503, 1979.

[1]  C. Rizzi.  Statistical Methods , 2020, Springer Theses.

[2]  M. Ohta,et al.  Immunotherapy of human lung cancer with BCG cell-wall skeleton. , 1976, Gan.

[3]  E. Ribi,et al.  IMMUNOTHERAPY WITH NONVIABLE MICROBIAL COMPONENTS , 1976, Annals of the New York Academy of Sciences.

[4]  W. Clark,et al.  Regression of pulmonary metastatic disease associated with intralesional bcg therapy of intracutaneous melanoma metastases , 1975 .

[5]  I. Azuma,et al.  Immunotherapy of cancer: tumor suppression and regression by cell walls of Mycobacterium phlei attached to oil droplets. , 1975, Journal of the National Cancer Institute.

[6]  J. Sokal,et al.  Complications of BCG vaccination in neoplastic disease. , 1975, Annals of internal medicine.

[7]  J. Smith,et al.  Nonspecific and specific immuno-suppression in tumour-bearing mice by soluble immune complexes , 1975, Nature.

[8]  W. R. Nelson,et al.  Immunotherapy of melanoma with BCG: Two fatalities following intralesional injection , 1975, Cancer.

[9]  R. Bast,et al.  BCG and cancer (first of two parts). , 2010, The New England journal of medicine.

[10]  Crispen Rg.  BCG vaccine in perspective. , 1974 .

[11]  L. Nathanson.  Use of BCG in the treatment of human neoplasms: a review. , 1974, Seminars in oncology.

[12]  B. Zbar,et al.  Biologically active components from mycobacterial cell walls. I. Isolation and composition of cell wall skeleton and component P3. , 1974, Journal of the National Cancer Institute.

[13]  M. Mastrangelo,et al.  Immunotherapy of melanoma with intralesional BCG. , 1973, National Cancer Institute monograph.

[14]  H. Wigzell,et al.  SURFACE MARKERS ON HUMAN T AND B LYMPHOCYTES , 1972, The Journal of experimental medicine.

[15]  D. Morton,et al.  Immunological factors which influence response to immunotherapy in malignant melanoma. , 1970, Surgery.

[16]  M. Polley,et al.  Human Monocytes: Distinct Receptor Sites for the Third Component of Complement and for Immunoglobulin G , 1968, Science.

[17]  A. Böyum.  Isolation of leucocytes from human blood. Further observations. Methylcellulose, dextran, and ficoll as erythrocyteaggregating agents. , 1968, Scandinavian journal of clinical and laboratory investigation. Supplementum.